That is in addition to the brokers that traded with Westpac that morning, including JPMorgan, Citi, ANZ, Goldman Sachs and Nomura, which may have...
You can now follow your favourite workout routine, get to deep work with LoFi music, or do a quick meditation session from the comfort of your Mac BENGALURU, India, May 1, 2021 /PRNewswire/ -- Global health and fitness platform Ultrahuman officially launched its Mac app to help users meditate, get to deep work with LoFi music & productivity playlists, & even workout from the comfort of their Mac.With the launch of the beautifully designed Mac app, accessing content from the world's best fitness experts has become even more seamless and simple."Office workers spend a jaw-dropping 1,700 hours a year in front of a computer - and that's just in the US. With Ultrahuman Mac app launch, our users' favourite work screen is now their favourite workout, mindfulness and sleep destination as well! Within a few days of launch, we were trending on #1 on Mac Store which also shows that people need seamless and quick access to their favourite relaxation, productivity and fitness apps, especially as we embrace the Work From Home culture," said Mohit Kumar, Founder & CEO, Ultrahuman.More about Ultrahuman
Ultrahuman is a fitness platform that helps people meditate, workout efficiently, and optimize their sleep with the help of athletes, neuroscientists, artists, and psychologists—all in one place. It was officially launched at the world's largest tech exhibition, CES, in January 2021.The core differentiator of the Ultrahuman app is bringing the best athletes, fitness coaches and psychologists in the world on one platform. Partners include leading athletes and celebrities like Crossfit world champion Kara Saunders, fitness celebrity Amanda Cerny, coach Johannes Bartl, hybrid athlete, and coach Kris Gethin, MindSize CEO Christian Straka, UCLA Mindfulness Director Diana Winston, to name a few.Biofeedback TechnologyCompared to Calm and Headspace's celebrity content approach—Ultrahuman uses a technology platform-based approach to improve the experience and sustainable long-term results.The Ultrahuman app integrates with the Apple Watch to provide real-time biofeedback to measure and improve the efficacy of meditation and workouts. You can not only see the calories burned and your heart rate but also track your progress day-on-day. Also, for the first time, you can see the impact of your meditation session with a drop in your heart rate as you feel less stressed and more relaxed.
Ever-growing fitness content library from top global expertsUltrahuman features an ever-growing library of thousands of hours of content across Body Workouts, Meditation, Bedtime Stories, and Brain Music categories designed by experts to empower users to unleash their personal best in mind and body.● Workouts: There are body Body Workout programs - including HIIT classes, Yoga, running, and more designed for all fitness levels. What makes each program unique is the combination of mind, body, and recovery that empowers users to maximize results and stay focused on consistent practice.● Meditation: The life-changing skill of meditation backed by cutting-edge research is the core of the experience.● Bedtime Stories: Bedtime Stories written by award-winning authors are designed to educate, delight, and relax users into sleep.
● Brain Music: Music from various neuro-musicians, classical music legends, and artists, including Grammy Award winners, is designed to relax, help with focus and productivity, sleep, and more.Assets are available for download here. Press Contact - firstname.lastname@example.orgAbout Ultrahuman: Ultrahuman is a fitness platform that helps people meditate, workout efficiently, and optimize their sleep with the help of athletes, neuroscientists, artists, and psychologists—all in one place. Ultrahuman is available on iOS, Android, Mac, Apple Watch, Wear OS. Follow us on Twitter, Facebook, Instagram, and LinkedIn.Related FilesUltrahuman Mac App Press Release.pdf
Related Imagesultrahuman.png UltrahumanHolistic Fitness App
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE:JNJ) and Roche Holding AG (OTC:RHHBY) each reported fairly robust results.
Four healthcare stocks, including biotechs and medical device makers, debuted on Wall Street this week, raising $413.3 million in gross proceeds.
Ocugen, Inc. (NASDAQ:OCGN) was among the biggest gainers of the week, having advanced over 110% on the back of a positive clinical readout for a partnered COVID-19 vaccine candidate.
Here are the key catalysts for the unfolding week:
International Organization for Medical Physics', or IOMP, International Medical Physics Week: April 26-30UBS Asia Virtual Healthcare Summit: April 27-29B. Riley's Neuroscience Investor Conference: April: April 28—292021 Society of Biological Psychiatry, or SOBP, annual meeting: April 29-May 1Association for Research In Vision and Ophthalmology, or ARVO, 2021 Virtual Meeting: May 1-7
The Food and Drug Administration is scheduled to announce its verdict on Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) new drug application for Epsolay in the treatment of inflammatory lesions of rosacea. The PDUFA date, or the deadline for announcing the decision, is Monday.
The FDA will also rule on Protalix BioTherapeutics, Inc.'s (NYSE:PLX) biologic license application for pegunigalsidase alfa in Fabry disease. The PDUFA date is set for Tuesday.
By Thursday, the regulatory agency is mandated to make a decision on Ardelyx, Inc.'s (NASDAQ:ARDX) new drug application for tenapanor in hyperphosphatemia.
Related Link: BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
Nanobiotix S.A. (NASDAQ:NBTX) is scheduled to present at the IOMP's physics week, further data from the Phase 1 expansion data for NBTXR3 in head and neck cancer.
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) will host a webinar at 8 a.m., Tuesday, to provide a corporate update on clinical programs for its CY6463 in Alzheimer's disease with vascular pathology and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.
Trillium Therapeutics Inc. (NASDAQ:TRIL) will host its virtual R&D Day for analysts and investors at 10:00 am – 1:00 pm on Wednesday, wherein it will provide a clinical update for TTI-622 in refractory lymphoma or multiple myeloma, and TTI-621 in diffuse Large B-cell Lymphoma (DLBCL), cutaneous T-cell lymphoma.
Aptinyx Inc. (NASDAQ:APTX) is due to present at the SOBP annual meeting, data from the Phase 2a exploratory study of NYX-783 in posttraumatic stress disorder.
Annovis Bio, Inc. (NYSE:ANVS) is scheduled to release in April interim data for ANVS401 in Alzheimer's and Parkinson's diseases.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is set to present at the ARVO annual meeting updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) (before the market open)Masimo Corporation (NASDAQ:MASI) (after the close)
Eli Lilly and Company (NYSE:LLY) (before the market open)AtriCure, Inc. (NASDAQ:ATRC) (after the close)Amgen Inc. (NASDAQ:AMGN) (after the close)Illumina, Inc. (NASDAQ:ILMN) (after the close)
Boston Scientific Corporation (NYSE:BSX) (before the market open)Surmodics, Inc. (NASDAQ:SRDX) (before the market open)Integra LifeSciences Holdings Corporation (NASDAQ:IART) (before the market open)Alkermes plc (NASDAQ:ALKS) (before the market open)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) (after the close)Alimera Sciences, Inc. (NASDAQ:ALIM) (after the close)OPKO Health, Inc. (NASDAQ:OPK) (after the close)Hologic, Inc. (NASDAQ:HOLX) (after the close)Viking Therapeutics, Inc. (NASDAQ:VKTX) (after the close)
Syneos Health, Inc. (NASDAQ:SYNH) (before the market open)NovoCure Limited (NASDAQ:NVCR) (before the market open)West Pharmaceutical Services, Inc. (NYSE:WST) (before the market open)Merck & Co., Inc. (NYSE:MRK) (before the market open)Evelo Biosciences, Inc. (NASDAQ:EVLO) (before the market open)Baxter International Inc. (NYSE:BAX) (before the market open)Bristol-Myers Squibb Company (NYSE:BMY) (before the market open)Blueprint Medicines Corporation (NASDAQ:BPMC) (before the market open)Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (before the market open)Laboratory Corporation of America Holdings (NYSE:LH) (before the market open)Abiomed, Inc. (NASDAQ:ABMD) (before the market open)Amarin Corporation plc (NASDAQ:AMRN) (before the market open)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) (before the market open)ResMed Inc. (NYSE:RMD) (after the close) (after the close)MiMedx Group, Inc. (NASDAQ:MDXG) (after the close)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the close)Pacific Biosciences of California, Inc. (NASDAQ:PACB) (after the close)Bio-Rad Laboratories, Inc. (NYSE:BIO) (after the close)Emergent BioSolutions Inc. (NYSE:EBS) (after the close)ChemoCentryx, Inc. (NASDAQ:CCXI) (after the close)DexCom, Inc. (NASDAQ:DXCM) (after the close)Gilead Sciences, Inc. (NASDAQ:GILD) (after the close)Merit Medical Systems, Inc. (NASDAQ:MMSI) (after the close)LeMaitre Vascular, Inc. (NASDAQ:LMAT) (after the close)MacroGenics, Inc. (NASDAQ:MGNX) (after the close)Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (after the close)Seagen Inc. (NASDAQ:SGEN) (after the close)
AbbVie Inc. (NYSE:ABBV) (before the market open)
IPOs Quiet Period Expiries
Achilles Therapeutics plc (NASDAQ:ACHL)
Related Link: Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline